Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Esperion Therapeutics, Inc. (ESPR) incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred a loss of 37 cents per share in the year-ago quarter.Esperion generated revenues of $51.6 million, up nearly 52% year over year, driven by higher collaboration revenues and product revenues in the United States. However, the reported figure missed the Zacks Consensus Estimate of$ 55 million.Shares of Esperion ...